AIM: Recent studies have suggested that intravenous (i.v.) enoxaparin could be used as antithrombotic therapy in patients ongoing percutaneous coronary intervention (PCI). However, anti-Xa pharmacokinetics following different i.v. dosing regimens is not clearly established. METHODS: A population pharmacokinetic analysis was developed using anti-Xa activities measured in 546 patients who received a single 0.5 mg kg(-1) i.v. dose of enoxaparin immediately before PCI. Effects of higher doses (0.75 mg kg(-1) and 1 mg kg(-1)) and/or additional bolus after the initial administration were similarly simulated. RESULTS: Enoxaparin anti-Xa time profiles were best described by a one-compartment model with zero-order kinetics. Mean population parameters (intersubject variability, %) were CL 1.2 l h(-1) (33), V 2.9 l (30) and zero-order input 0.25 h (24). With a single bolus of 0.5 mg kg(-1), the totality of the patients reached an effective anticoagulation level (anti-Xa >0.5 IU ml(-1)) and only 2.5% reached levels above 1.5 IU ml(-1). Simulations showed that greater doses (0.75 mg kg(-1) and 1 mg kg(-1)) prolonged the duration of anticoagulation (3.4 and 4.1 h, respectively) compared with the 0.5 mg kg(-1) bolus (2.7 h) and markedly increased the proportion (48% and 79%, respectively) of patients with anti-Xa levels >1.5 IU ml(-1). For delayed and/or prolonged procedures, patients could be administered a second bolus of half the initial dose in a time interval between 90 min to 2 h after in order to maintain similar anticoagulation profile levels. CONCLUSIONS: A single 0.5 mg kg(-1) i.v. dose of enoxaparin reached anticoagulation levels adequately and should be safer compared with greater doses for anticoagulation in patients undergoing an elective PCI. An additional second bolus could be proposed in patients with delayed or prolonged procedures.
AIM: Recent studies have suggested that intravenous (i.v.) enoxaparin could be used as antithrombotic therapy in patients ongoing percutaneous coronary intervention (PCI). However, anti-Xa pharmacokinetics following different i.v. dosing regimens is not clearly established. METHODS: A population pharmacokinetic analysis was developed using anti-Xa activities measured in 546 patients who received a single 0.5 mg kg(-1) i.v. dose of enoxaparin immediately before PCI. Effects of higher doses (0.75 mg kg(-1) and 1 mg kg(-1)) and/or additional bolus after the initial administration were similarly simulated. RESULTS:Enoxaparin anti-Xa time profiles were best described by a one-compartment model with zero-order kinetics. Mean population parameters (intersubject variability, %) were CL 1.2 l h(-1) (33), V 2.9 l (30) and zero-order input 0.25 h (24). With a single bolus of 0.5 mg kg(-1), the totality of the patients reached an effective anticoagulation level (anti-Xa >0.5 IU ml(-1)) and only 2.5% reached levels above 1.5 IU ml(-1). Simulations showed that greater doses (0.75 mg kg(-1) and 1 mg kg(-1)) prolonged the duration of anticoagulation (3.4 and 4.1 h, respectively) compared with the 0.5 mg kg(-1) bolus (2.7 h) and markedly increased the proportion (48% and 79%, respectively) of patients with anti-Xa levels >1.5 IU ml(-1). For delayed and/or prolonged procedures, patients could be administered a second bolus of half the initial dose in a time interval between 90 min to 2 h after in order to maintain similar anticoagulation profile levels. CONCLUSIONS: A single 0.5 mg kg(-1) i.v. dose of enoxaparin reached anticoagulation levels adequately and should be safer compared with greater doses for anticoagulation in patients undergoing an elective PCI. An additional second bolus could be proposed in patients with delayed or prolonged procedures.
Authors: C P Cannon; A Battler; R G Brindis; J L Cox; S G Ellis; N R Every; J T Flaherty; R A Harrington; H M Krumholz; M L Simoons; F J Van De Werf; W S Weintraub; K R Mitchell; S L Morrisson; R G Brindis; H V Anderson; D S Cannom; W R Chitwood; J E Cigarroa; R L Collins-Nakai; S G Ellis; R J Gibbons; F L Grover; P A Heidenreich; B K Khandheria; S B Knoebel; H L Krumholz; D J Malenka; D B Mark; C R Mckay; E R Passamani; M J Radford; R N Riner; J B Schwartz; R E Shaw; R J Shemin; D B Van Fossen; E D Verrier; M W Watkins; D R Phoubandith; T Furnelli Journal: J Am Coll Cardiol Date: 2001-12 Impact factor: 24.094
Authors: J P Collet; G Montalescot; L Lison; R Choussat; A Ankri; G Drobinski; I Sotirov; D Thomas Journal: Circulation Date: 2001-02-06 Impact factor: 29.690
Authors: Rémi Choussat; Gilles Montalescot; Jean Philippe Collet; Eric Vicaut; Annick Ankri; Vanessa Gallois; Gérard Drobinski; Ivan Sotirov; Daniel Thomas Journal: J Am Coll Cardiol Date: 2002-12-04 Impact factor: 24.094
Authors: Richard C Becker; Frederick A Spencer; Michael Gibson; Janet E Rush; Gerard Sanderink; Sabina A Murphy; Steven P Ball; Elliott M Antman Journal: Am Heart J Date: 2002-05 Impact factor: 4.749
Authors: D J Kereiakes; C Grines; E Fry; P Esente; D Hoppensteadt; M Midei; L Barr; W Matthai; M Todd; T Broderick; R Rubinstein; J Fareed; E Santoian; A Neiderman; B Brodie; J Zidar; J J Ferguson; M Cohen Journal: J Invasive Cardiol Date: 2001-04 Impact factor: 2.022
Authors: Muhammad Shakil Aslam; Steve Sundberg; M Nagui Sabri; David Cooke; Jeffrey B Lakier Journal: Catheter Cardiovasc Interv Date: 2002-10 Impact factor: 2.692
Authors: Robert C Welsh; Cynthia M Westerhout; Christopher E Buller; Blair O'Neill; Phillip Gordon; Paul W Armstrong Journal: J Thromb Thrombolysis Date: 2012-07 Impact factor: 2.300
Authors: Wael Sumaya; William A E Parker; Rebekah Fretwell; Ian R Hall; David S Barmby; James D Richardson; Javaid Iqbal; Zulfiquar Adam; Kenneth P Morgan; Julian P Gunn; Annah E Mason; Heather M Judge; Christopher P Gale; Ramzi A Ajjan; Robert F Storey Journal: Thromb Haemost Date: 2018-06-06 Impact factor: 5.249
Authors: Wael Sumaya; William A E Parker; Heather M Judge; Ian R Hall; Rachel C Orme; Zulfiquar Adam; James D Richardson; Alexander M K Rothman; Kenneth P Morgan; Julian P Gunn; Robert F Storey Journal: Platelets Date: 2020-06-16 Impact factor: 3.862